Jose G Romano1, Eric E Smith2, Li Liang3, Hannah Gardener1, Sara Camp4, Laura Shuey4, Alison Cook4, Iszet Campo-Bustillo1, Pooja Khatri5, Deepak L Bhatt6, Gregg C Fonarow7, Ralph L Sacco1, Lee H Schwamm8. 1. Department of Neurology, University of Miami Miller School of Medicine, Miami, Florida. 2. Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada. 3. Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina. 4. American Heart Association, Dallas, Texas. 5. Department of Neurology, University of Cincinnati, Cincinnati, Ohio. 6. Department of Medicine, Brigham and Women's Hospital Heart & Vascular Center/Harvard Medical School, Boston, Massachusetts. 7. Department of Medicine, University of California, Los Angeles. 8. Department of Neurology, Massachusetts General Hospital/Harvard Medical School, Boston.
Abstract
IMPORTANCE: Mild strokes have been poorly represented in thrombolytic trials and only a few series have reported outcomes after treatment with intravenous (IV) recombinant tissue plasminogen activator (rtPA) after mild stroke. OBJECTIVE: To report treatment complications and short-term outcomes in patients with mild stroke who have received treatment with IV rtPA. DESIGN, SETTING, AND PARTICIPANTS: Retrospective analysis of patients treated in the emergency department of hospitals that use the Get With the Guidelines-Stroke registry, a prospectively collected quality improvement registry used by hospitals across the United States. Patients were those admitted between May 1, 2010, and October 1, 2012, with acute ischemic stroke within 4.5 hours from symptom onset and a baseline National Institutes of Health Stroke Scale score of 5 or less. Univariable and multivariable analyses were performed to identify factors independently associated with discharge outcomes and treatment complications. INTERVENTION: Intravenous rtPA. MAIN OUTCOMES AND MEASURES: Treatment complications included symptomatic intracranial hemorrhage, life-threatening or serious systemic hemorrhage, other serious complications, and undetermined complications. The short-term outcomes analyzed were in-hospital mortality, discharge to home, independent ambulation at discharge, and length of stay. RESULTS: Among 33,995 patients who arrived within 4.5 hours of symptom onset and were treated with IV rtPA, 7621 (22.4%) had a National Institutes of Health Stroke Scale score of 5 or less and 5910 had complete data for analysis. Treatment complications were infrequent: symptomatic intracranial hemorrhage, 1.8%; life-threatening or serious systemic hemorrhage, 0.2%; other serious complications, 1.8%; and complications of undetermined cause, 2.4%. Mortality was low (1.3%), but at discharge 30.3% could not ambulate independently, 29.4% could not go directly home, and 73.0% had a length of stay of 3 days or longer. Worse short-term outcomes were seen in older patients, African American patients, diabetic patients, and those who arrived by ambulance, after hours, or with a higher National Institutes of Health Stroke Scale score. CONCLUSIONS AND RELEVANCE: Many patients with ischemic stroke treated with IV rtPA have a mild stroke. Symptomatic intracranial hemorrhage is infrequent, but approximately 30% of these patients are unable to return directly home or ambulate independently at discharge. Additional studies are needed to identify strategies to improve the outcomes in patients with mild stroke who receive thrombolysis.
IMPORTANCE: Mild strokes have been poorly represented in thrombolytic trials and only a few series have reported outcomes after treatment with intravenous (IV) recombinant tissue plasminogen activator (rtPA) after mild stroke. OBJECTIVE: To report treatment complications and short-term outcomes in patients with mild stroke who have received treatment with IV rtPA. DESIGN, SETTING, AND PARTICIPANTS: Retrospective analysis of patients treated in the emergency department of hospitals that use the Get With the Guidelines-Stroke registry, a prospectively collected quality improvement registry used by hospitals across the United States. Patients were those admitted between May 1, 2010, and October 1, 2012, with acute ischemic stroke within 4.5 hours from symptom onset and a baseline National Institutes of Health Stroke Scale score of 5 or less. Univariable and multivariable analyses were performed to identify factors independently associated with discharge outcomes and treatment complications. INTERVENTION: Intravenous rtPA. MAIN OUTCOMES AND MEASURES: Treatment complications included symptomatic intracranial hemorrhage, life-threatening or serious systemic hemorrhage, other serious complications, and undetermined complications. The short-term outcomes analyzed were in-hospital mortality, discharge to home, independent ambulation at discharge, and length of stay. RESULTS: Among 33,995 patients who arrived within 4.5 hours of symptom onset and were treated with IV rtPA, 7621 (22.4%) had a National Institutes of Health Stroke Scale score of 5 or less and 5910 had complete data for analysis. Treatment complications were infrequent: symptomatic intracranial hemorrhage, 1.8%; life-threatening or serious systemic hemorrhage, 0.2%; other serious complications, 1.8%; and complications of undetermined cause, 2.4%. Mortality was low (1.3%), but at discharge 30.3% could not ambulate independently, 29.4% could not go directly home, and 73.0% had a length of stay of 3 days or longer. Worse short-term outcomes were seen in older patients, African American patients, diabeticpatients, and those who arrived by ambulance, after hours, or with a higher National Institutes of Health Stroke Scale score. CONCLUSIONS AND RELEVANCE: Many patients with ischemic stroke treated with IV rtPA have a mild stroke. Symptomatic intracranial hemorrhage is infrequent, but approximately 30% of these patients are unable to return directly home or ambulate independently at discharge. Additional studies are needed to identify strategies to improve the outcomes in patients with mild stroke who receive thrombolysis.
Authors: Fadar Oliver Otite; Priyank Khandelwal; Seemant Chaturvedi; Jose G Romano; Ralph L Sacco; Amer M Malik Journal: Neurology Date: 2016-10-12 Impact factor: 9.910
Authors: Sara K Rostanski; Zachary Shahn; Mitchell S V Elkind; Ava L Liberman; Randolph S Marshall; Joshua I Stillman; Olajide Williams; Joshua Z Willey Journal: Stroke Date: 2017-05-23 Impact factor: 7.914
Authors: Shahram Majidi; Marie Luby; John K Lynch; Amie W Hsia; Richard T Benson; Chandni P Kalaria; Zurab Nadareishvili; Lawrence L Latour; Richard Leigh Journal: Neurology Date: 2019-09-13 Impact factor: 9.910
Authors: Tracy E Madsen; Heidi Sucharew; Brian Katz; Kathleen A Alwell; Charles J Moomaw; Brett M Kissela; Matthew L Flaherty; Daniel Woo; Pooja Khatri; Simona Ferioli; Jason Mackey; Sharyl Martini; Felipe De Los Rios La Rosa; Dawn Kleindorfer Journal: J Stroke Cerebrovasc Dis Date: 2015-11-23 Impact factor: 2.136
Authors: J Pfaff; C Herweh; M Pham; S Schönenberger; S Nagel; P A Ringleb; M Bendszus; M Möhlenbruch Journal: AJNR Am J Neuroradiol Date: 2016-06-30 Impact factor: 3.825
Authors: Negar Asdaghi; Kefeng Wang; Maria A Ciliberti-Vargas; Carolina Marinovic Gutierrez; Sebastian Koch; Hannah Gardener; Chuanhui Dong; David Z Rose; Enid J Garcia; W Scott Burgin; Juan Carlos Zevallos; Tatjana Rundek; Ralph L Sacco; Jose G Romano Journal: Stroke Date: 2018-02-19 Impact factor: 7.914
Authors: Michael V Mazya; Charith Cooray; Kennedy R Lees; Danilo Toni; Gary A Ford; Michal Bar; Senta Frol; Tiago Moreira; Lakshmanan Sekaran; Viktor Švigelj; Nils Wahlgren; Niaz Ahmed Journal: Eur Stroke J Date: 2017-11-29
Authors: Ava L Liberman; Daniel Pinto; Sara K Rostanski; Daniel L Labovitz; Andrew M Naidech; Shyam Prabhakaran Journal: Neurohospitalist Date: 2018-09-13